Immune cell engagers are engineered antibodies with at least one arm binding a tumor-
associated antigen and at least another one directed against an activating receptor in …

The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic
shift since the dawn of the current century. This has been driven largely by the introduction of …

Abstract Non-Hodgkin's Lymphoma (NHL) remains a significant challenge in hematology,
with chemotherapy and radiation therapy as conventional treatment options, albeit with …

Introduction Therapeutic strategies against multiple myeloma (MM) have evolved
dramatically in recent decades, with unprecedent results in the treatment landscape …

This case report describes the development of Progressive Multifocal Leukoencephalopathy
(PML) in a 72-year-old male with relapsed/refractory multiple myeloma (RRMM), following a …

多发性骨髓瘤是骨髓浆细胞来源的血液系统恶性肿瘤, 目前认为无法治愈且绝大多数患者最终
发展为复发/难治性多发性骨髓瘤. 双特异性抗体治疗是一种新兴的免疫治疗手段 …

Background The plasma cell malignancy, multiple myeloma (MM), remains incurable
despite advanced treatment protocols. Overexpression of Bcl-2 (an anti-apoptotic protein), in …

El mieloma múltiple (MM) es una enfermedad altamente heterogénea e incurable; aún con
los grandes avances que ha tenido el campo en los últimos 20 años, la gran mayoría de los …

Dear Editor, Multiple myeloma (MM) is a tumor of the plasma cell. This heterogeneous
monoclonal malignancy accounts for about 15% of all yearly reported hematological tumor …

Multiple myeloma is a hematologic malignancy originating from bone marrow plasma cells
and remains incurable. Most patients eventually develop into relapsed/refractory multiple …